

Taro Pharmaceuticals U.S.A., Inc.

Vermont New Product Launch Report

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE	WAC AT INTRODUCTION	MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC	ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR	ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC	ACQUISITION PRICE COMMENT	GENERAL COMMENTS
51672423704	Deferiprone 1000mg 50ct	3/7/2024	\$6,975.58	As this is a generic pharmaceutical product, Taro does not engage in marketing activities typically attendant to branded products. There are no direct to consumer marketing activities of any kind, and no promotion of the product to physicians or other healthcare providers. Taro contracts with specialty pharmacies and wholesalers. Taro utilized appropriate pricing planning based on current and predicted market conditions. In this instance, utilizing only publically available information Sun determined aligning WAC with other generic companies already in the market would enable it to maximize sales and minimize competitive risk.	N	200,000	N	N			Y/N		

Key **Used for Full Report Due 30 Days After In:**
 Submissions Made To AGO.highcostprescriptiondrugs@vermont.gov